Interim Postmarket Data Release May Compromise Trials – FDA Panel
Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26
Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26